Key indicators: single-crystal X-ray study; T = 298 K; mean (C-C) = 0.002 Å; R factor = 0.037; wR factor = 0.038; data-to-parameter ratio = 12.8.
Related literature
For the synthesis of the title compound, see: Kumar et al. (2009) . For background to this class of anti-ulcer drugs, see: Arimori et al. (1998) ; Masa et al. (2001) . For a related structure, see: Fujishima et al. (2002) .
Experimental
Crystal data 
Data collection
Rigaku Mercury diffractometer Absorption correction: multi-scan (REQAB; Jacobson, 1998) T min = 0.942, T max = 0.950 7636 measured reflections 2752 independent reflections 2601 reflections with F 2 > 2(F 2 ) R int = 0.025 Refinement R[F 2 > 2(F 2 )] = 0.037 wR(F 2 ) = 0.038 S = 1.25 2752 reflections 215 parameters H atoms treated by a mixture of independent and constrained refinement Á max = 0.48 e Å À3 Á min = À0.37 e Å À3 Absolute structure: Flack (1983) , with 1292 Friedel pairs Flack parameter: À0.02 (4) Table 1 Hydrogen-bond geometry (Å , ). (Betteridge et al. 2003) ; molecular graphics: X-SEED (Barbour, 2001) ; software used to prepare material for publication: CrystalStructure.
M. Naga Raju, N. Uday Kumar, N. Kolla, R. Bandichhor and P. Vishweshwar
Comment
Dexlansoprazole II ((R)-(+)) ( Fig. 1) , (R)-enantiomer of Lansoprazole, is a proton pump inhibitor (PPI) mainly developed for anti-ulcer activity by TAP Pharmaceuticals Ltd., employing new modified-release technology (Arimori et al. 1998; Masa et al. 2001) . Dexlansoprazole II ((R)-(+)) was first approved by United States Food and Drug Administration (US-FDA) in the form of 30 and 60 mg capsules for the management of patients with erosive oesophagitis and non-erosive reflux disease (GERD or GORD), under the brand name of DEXILANT.
An alternative and large-scale synthetic method for II ((R)-(+)) was developed in our laboratory by employing asymmetric oxidation conditions on prochiral nitrosulfide intermediate to yield enantiomerically enriched nitro sulphoxide derivative of the title compound I ((R)-(+)) as first stage intermediate (>90% ee) (Kumar et al. 2009 ). Titanium derived chiral complex (2.2:1.1:0.6 ratio of Titanium (IV)-i-propoxide:(+)-Diethyl L-tartrate:Water) was used in the reaction to induce the chirality.
The enantiomerically enriched title compound I ((R)-(+)) as a resultant was subjected to acetone mediated crystallization to yield enantiopure I ((R)-(+)) (>97% ee) which on treatment with potassium salt of 2,2,2-triflouroethanol in dimethylformamide (DMF) yielded Dexlansoprazole II ((R)-(+)) with ICH quality having >99.8% ee.
The structure and stereochemistry of Dexlansoprazole II ((R)-(+)) was well established in the literature with various spectroscopic and single-crystal X-ray diffraction (Fujishima et al. 2002) . Herein we have determined the absolute configuration of the title compound I as `R' by anomalous dispersion (Fig. 2) . The Flack parameter value, -0.02 (4) for the assigned absolute configuration, suggest that it is correct with high accuracy. The title compound is enantipure sulphoxide containing substituents of benzimidazole and 2-(3-methyl-4-nitro-pyridin-2-yl) methane moieties with dextro (d)-optical configuration. The crystal structure reveals that title molecules are forming chains along the b axis through N 1 -H···N 2 and C 2 -H···O 1 hydrogen-bonded dimers. Such chains are connected via weak C 12 -H···O 2 hydrogen bonds ( Fig. 3) .
Experimental
A mixture of enantiomerically enriched title compound I ((R)-(+)) (12 g, 0.038 mol) and acetone (264 ml) were heated to 45-50 °C until clear solution obtained. The resulting clear solution was cooled to -5 to 0 °C and stirred for 1.0-1.5 h. The precipitated I (RS)-(±) was filtered and the filtrate was evaporated under vacuum at below 45 °C to obtain thick residue of the title compound I ((R)-(+)). The resulting thick residue of the title compound I ((R)-(+)) was dissolved in dichloromethane and kept for slow solvent evaporation to grow single crystals.
Refinement
The C-bound H atoms were geometrically placed (C-H = 0.95 Å) and refined as riding with U iso (H) = 1.2Ueq(parent atom). 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq S1 0.23549 (4) 0.46611 (4) 0.34638 (4) 0.0355 (1) (4) O2 0.0521 (7) 0.0478 (7) 0.0793 (9) −0.0140 (6) 0.0116 (6) −0.0158 (6) O3 0.0467 (6) 0.1104 (13) 0.0441 (6) −0.0083 (7) −0.0019 (5) −0.0079 (7) N1 0.0350 (7) 0.0330 (6) 0.0412 (7) 0.0040 (5) 0.0029 (6) 0.0029 (6) N2 0.0302 (6) 0.0355 (6) 0.0401 (7) −0.0010 (5) 0.0015 (5) 0.0009 (6) N3 0.0369 (7) 0.0406 (7) 0.0516 (8) −0.0051 (5) 0.0110 (6) −0.0030 (5) N4 0.0320 (6) 0.0581 (9) 0.0502 (7) −0.0062 (7) 0.0088 (5) −0.0179 (8) C1 0.0258 (5) 0.0395 (7) 0.0381 (6) −0.0008 (7) 0.0030 (4) −0.0012 (8) C2
0.0389 (8) 0.0372 (8) 0.0435 (8) 0.0058 (7) 0.0028 (7) 0.0037 (7) C3 0.0322 (7) 0.0528 (10) 0.0399 (8) 0.0058 (6) −0.0043 (6) 0.0029 (7) C4 0.0360 (8) 0.0552 (9) 0.0414 (9) −0.0054 (7) −0.0019 (7) −0.0057 (8) C5
0.0401 (8) 0.0343 (7) 0.0480 (9) −0.0037 (6) 0.0053 (7) −0.0025 (7) (6) 0.0053 (7) C13 0.0431 (9) 0.0355 (7) 0.0566 (9) 0.0007 (6) 0.0097 (7) 0.0000 (7) C14 0.0431 (9) 0.0394 (8) 0.0812 (13) 0.0029 (7) 0.0172 (9) 0.0010 (8) Geometric parameters (Å, °) S1-O1 1.4831 (12) C6-C7 1.396 (2) S1-C1 1.7806 (13) C8-C9 1.515 (2) S1-C8 
